Telomir Pharmaceuticals, Inc. (TELO)
0.88
+0.10
(+12.81%)
USD |
NASDAQ |
Nov 06, 10:32
Telomir Pharmaceuticals Shareholders Equity (Quarterly) : 5.034M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 5.034M |
| March 31, 2026 | 4.962M |
| December 31, 2025 | 5.913M |
| September 30, 2025 | 6.979M |
| June 30, 2025 | 0.4812M |
| March 31, 2025 | -0.1611M |
| December 31, 2024 | 0.643M |
| September 30, 2024 | 0.4421M |
| Date | Value |
|---|---|
| June 30, 2024 | 1.568M |
| March 31, 2024 | 3.017M |
| December 31, 2023 | 3.438M |
| September 30, 2023 | 2.178M |
| June 30, 2023 | 3.889M |
| March 31, 2023 | |
| December 31, 2022 | -0.9373M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 597.21M |
| Corcept Therapeutics, Inc. | 833.74M |
| Veru, Inc. | 28.38M |
| Johnson & Johnson | 81.53B |
| Eli Lilly & Co. | 40.27B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 5.366M |
| Total Liabilities (Quarterly) | 0.3324M |
| Debt to Equity Ratio | 0.0271 |
| Current Ratio | 16.14 |
| Net Debt Paydown Yield | -0.03% |